Engineered Un1Cas12f1 for multiplex genome editing with enhanced activity and targeting scope - PubMed
2 days ago
- #Genome Editing
- #Therapeutic Engineering
- #CRISPR
- Engineered Un1Cas12f1 (evoCas12f) enhances genome editing with expanded PAM recognition (NTNR/NYTR).
- evoCas12f reduces median PAM site distance to 2 nucleotides in the human genome.
- Achieves 1.4-fold higher activity at TTTR sites and up to 91% editing efficiency.
- Enables efficient homozygous mutations in F0 generation mice, even at non-canonical PAM sites.
- Adapted for transcriptional activation and precise base editing with a defined window.
- Compact and efficient, suitable for multiplexed editing and therapeutic genome engineering.
- Patent applications filed based on evoCas12f technology.